CEO Corner

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of.  To submit a CEO Corner article, please follow these guidelines.

  • Winning With The Right Marbles: The Future of Generics

    After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO Stephen Beckman.

  • Planning For Perseverance

    AC Immune SA cofounder and CEO Andrea Pfeifer offers lessons in strategy and resilience for building and maintaining a drug development company amid internal and external ups and downs.

  • Leading Through Biotech's Perfect Storm: Lessons From The Front Lines

    Memo Therapeutics CEO Erik van den Berg reflects on the strategies and skills needed to build company resilience and navigate successfully through challenging external circumstances.

  • How To Lead a Company That's Disrupting An Industry

    Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.

  • From Bike Mechanic To Surgeon To CEO

    InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, surgeon, and biopharmaceutical leader.

  • Navigating Growth In Biotech: A First-Person Insight

    Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value.

  • Delivering The Next Evolution In Immuno-Oncology

    To continue the momentum created by new discoveries and treatments for cancer patients, drug developers need a strong and focused corporate culture, employees willing to challenge established norms, and a system for prioritizing development candidates guided by science and patient needs.

  • Facing The Drug Launch Challenge As A New CEO

    Economic instability, geopolitical struggles, market access, pricing, and regulatory differences — among many other issues — can present themselves at any time before, during, or after the launch. What is important is how a CEO manages the steps toward launch success.

  • Essential Elements Of Becoming A Successful CEO

    In this article, I address what it takes to succeed as a CEO by sharing insights and learnings from my own career in the hope that my experiences will offer some valuable guidance to those who aspire to become CEOs.

  • Making The Jump From Big Pharma To Biotech

    When a recruiter presented me with an opportunity to become CEO of a small but rising publicly listed biotech in my native Canada, I had to give it a lot of thought. Although I loved my job, I was a bit itchy to make not just a career move, but a life move.

BEYOND THE PRINTED PAGE

@LIFESCILEADER1